IAAF Publishes 2017 WADA Prohibited List
The International Association of Athletics Federations (IAAF) released the prohibited list of items to guide athletes and all their support personnel as they prepare for next year's championships year! The Prohibited list will come into effect from January 1st, 2017. In its statement issued from the Medical and anti-doping department, it strongly urged member associations to be aware of the changes which have been made by WADA in advance of its introduction in the New Year.
The IAAF also encouraged all athletes to use resources available from their national anti-doping organization for further information and to always access any useful tools like; www.globaldro.com to check whether medications are permitted or prohibited.
Four specific key links or pieces of information were shared for guidance, see below;
1. Access the 2017 Prohibited List here:
2. Read the WADA summary of modifications here:
3. Download the Prohibited List iPhone/iPad app here (note: currently reflects the 2016 version until January.
Athletes and/or support personnel in need of any further clarification with the list or have outstanding questions should always reach the antidoping helpdesk at; email@example.com
In addition to the information above, the IAAF also provided a short summary of key additions and clarification to the List in 2017 which athletes should be aware of. This information should not replace the need to access or refer to the full prohibited list.
Added in 2017:
· GATA inhibitors (e.g., K-11706) and Transforming Growth Factor- β (TGF-β) inhibitors (e.g., sotatercept, luspatercept)
· Lisdexamfetamine is currently prohibited. In 2017 it will be classed as a non-specified stimulant.
· Nicomorphine was added. It is an opioid analgesic drug, which is converted to morphine following administration.
Other important clarifications:
· Salbutamol: Dosing parameters of salbutamol were refined to make it clear that the full 24-hour dose should not be administered at one time; For inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours.
· Clarification that supplemental oxygen administered intravenously is prohibited, but administration by inhalation is permitted
· Higenamnie is documented to be a constituent of the plant Tinospora crispa, which can be found in some dietary supplements and is a prohibited non-selective beta-2-agonist.
The following were added to the 2017 Monitoring Programme to establish patterns of use:
ii. Concurrent use of multiple beta-2-agonists
· Clarification on Phenylethylamine: Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding.